

CITATION REPORT

List of articles citing

Role of peroxisome proliferator-activated receptor δ / β in hepatic metabolic regulation

DOI: 10.1074/jbc.m110.138115

Journal of Biological Chemistry, 2011, 286, 1237-47.

Source: <https://exaly.com/paper-pdf/52064219/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	Dissecting the role of peroxisome proliferator-activated receptor- γ (PPAR γ) in colon, breast, and lung carcinogenesis. 2011 , 30, 619-40		46
110	Phytoceramide and sphingoid bases derived from brewer's yeast <i>Saccharomyces pastorianus</i> activate peroxisome proliferator-activated receptors. 2011 , 10, 150		19
109	Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. 2011 , 54, 1966-74		24
108	Changes in the 24 h Rhythmicity of Liver PPARs and Peroxisomal Markers When Feeding Is Restricted to Two Daytime Hours. 2011 , 2011, 261584		15
107	Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. 2012 , 2012, 107434		56
106	PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. 2012 , 2012, 757803		40
105	Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways. 2012 , 18, 1665-72		93
104	Roles of PPARs in NAFLD: potential therapeutic targets. 2012 , 1821, 809-18		190
103	Increased fat mass is associated with increased bone size but reduced volumetric density in pre pubertal children. 2012 , 50, 562-7		61
102	Oleic acid activates peroxisome proliferator-activated receptor δ to compensate insulin resistance in steatotic cells. 2012 , 23, 1264-70		29
101	Activation of PPAR γ up-regulates the expression of insulin gene transcription factor MafA and ameliorates glucose-induced insulin secretion impaired by palmitate. 2012 , 366, 183-9		7
100	The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. 2012 , 12, 181-95		317
99	A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. 2013 , 502, 550-4		259
98	Physiology: A metabolic minuet. 2013 , 502, 454-5		2
97	Pharmacological agents for NASH. 2013 , 10, 676-85		52
96	Peroxisome proliferator-activated receptor delta and cardiovascular disease. 2013 , 231, 95-106		25
95	Free radical biology for medicine: learning from nonalcoholic fatty liver disease. 2013 , 65, 952-968		160

94	The TSC-mTOR pathway regulates macrophage polarization. 2013 , 4, 2834	322
93	Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. 2013 , 2013, 613864	61
92	Peroxisome proliferator-activated receptor α multifaceted metabolic player. 2013 , 24, 171-7	63
91	Hepatic genotoxicity and toxicogenomic responses in MutaMouse males treated with dibenz[a,h]anthracene. 2013 , 28, 543-54	17
90	Transcriptional repression of mitochondrial function in aging: a novel role for the silencing mediator of retinoid and thyroid hormone receptors co-repressor. 2013 , 19, 299-309	4
89	Molecular pathways in non-alcoholic fatty liver disease. 2014 , 7, 221-39	229
88	Retinoic acid-related orphan receptor γ (ROR γ) a novel participant in the diurnal regulation of hepatic gluconeogenesis and insulin sensitivity. 2014 , 10, e1004331	52
87	Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue. 2014 , 55, 104-14	38
86	PPAR δ activation attenuates hepatic steatosis in Ldlr $^{-/-}$ mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. 2014 , 55, 1254-66	49
85	The role of medications for the management of patients with NAFLD. 2014 , 18, 73-89	24
84	Diurnal regulation of lipid metabolism and applications of circadian lipidomics. 2014 , 41, 231-50	86
83	Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. 2014 , 34, 1133-52	47
82	Physiological functions of peroxisome proliferator-activated receptor α 2014 , 94, 795-858	104
81	Evolving therapies for non-alcoholic steatohepatitis. 2014 , 9, 687-96	9
80	Energy metabolism in the liver. 2014 , 4, 177-97	898
79	Lipid metabolites as metabolic messengers in inter-organ communication. 2014 , 25, 356-63	28
78	Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPAR δ Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity. 2014 , 8, 97-111	25
77	MuRF2 regulates PPAR δ activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet. 2015 , 14, 97	27

76	Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals. 2015 , 9, 5625-32	2
75	Integrative and systemic approaches for evaluating PPAR α (PPAR α) function. 2015 , 13, e001	40
74	PPAR α Required for PPAR α Action in Regulation of Body Weight and Hepatic Steatosis in Mice. 2015 , 2015, 927057	38
73	Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. 2015 , 7, 1012-9	107
72	PPAR α activation induces hepatic long-chain acyl-CoA synthetase 4 expression in vivo and in vitro. 2015 , 1851, 577-87	12
71	Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. 2015 , 127, 73-81	31
70	Transcriptomic analysis of hepatic responses to testosterone deficiency in miniature pigs fed a high-cholesterol diet. 2015 , 16, 59	21
69	Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet. 2015 , 15, 36	14
68	Metabolic Regulation by Nuclear Receptors. 2015 , 25-37	7
67	PPARs and ERRs: molecular mediators of mitochondrial metabolism. 2015 , 33, 49-54	136
66	A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice. 2016 , 2016, 9185987	17
65	PPARs and Mitochondrial Metabolism: From NAFLD to HCC. 2016 , 2016, 7403230	49
64	Transcriptional control of physiological and pathological processes by the nuclear receptor PPAR α . 2016 , 64, 98-122	45
63	Combined pharmacological activation of AMPK and PPAR α potentiates the effects of exercise in trained mice. 2016 , 4, e12625	20
62	PPAR α is a therapeutic target to rescue mitochondrial function in neurological disease. 2016 , 100, 153-163	111
61	Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2016 , 64, 955-65	172
60	Unraveling the Effects of PPAR α on Insulin Resistance and Cardiovascular Disease. 2016 , 27, 319-334	46
59	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. 2016 , 33, 291-319	54

58	Metabolic Rhythm of Hepatic Lipogenesis: Regulation and Roles in Metabolism. 2016 , 235-253	
57	PPAR δ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue. 2016 , 65, 829-39	59
56	Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. 2017 , 21, 333-348	40
55	Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor δ <i>Journal of Biological Chemistry</i> , 2017 , 292, 884-897	5.4 16
54	PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR δ and PPAR γ 2017 , 13, 279-296	97
53	Roles of Peroxisome Proliferator-Activated Receptor δ in skeletal muscle physiology. 2017 , 136, 42-48	33
52	Polydatin exhibits the hepatoprotective effects through PPAR δ signaling pathway in Streptozocin-induced diabetic mice. 2017 , 36, 341-347	10
51	Peroxisome proliferator-activated receptor delta facilitates lipid secretion and catabolism of fatty acids in dairy goat mammary epithelial cells. 2017 , 100, 797-806	19
50	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. 2017 , 13, 36-49	322
49	Peroxisome proliferator-activated receptor delta regulates lipid droplet formation and transport in goat mammary epithelial cells. 2018 , 101, 2641-2649	3
48	Multi-tissue transcriptomic study reveals the main role of liver in the chicken adaptive response to a switch in dietary energy source through the transcriptional regulation of lipogenesis. 2018 , 19, 187	17
47	Identification and characterization of cis-regulatory elements Unsilulator and repressor Un PPARD gene. 2018 , 10, 613-627	1
46	New therapeutic perspectives in non-alcoholic steatohepatitis. 2018 , 41, 128-142	
45	New therapeutic perspectives in non-alcoholic steatohepatitis. 2018 , 41, 128-142	8
44	Dual PPAR δ/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. 2018 , 38, 1084-1094	90
43	Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report. 2018 , 11, 901-911	4
42	Peroxisome Proliferator-Activated Receptor δ Supports the Metabolic Requirements of Cell Growth in TCR β Selected Thymocytes and Peripheral CD4 T Cells. 2018 , 201, 2664-2682	10
41	PPAR δ A Key Therapeutic Target in Metabolic Disorders. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3 44

40	Insights into the Role of PPAR γ in NAFLD. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	29
39	PPAR γ Linking Metabolism to Regeneration. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	40
38	Ameliorative effect of <i>Sedum sarmentosum</i> Bunge extract on Tilapia fatty liver via the PPAR and P53 signaling pathway. <i>Scientific Reports</i> , 2018 , 8, 8456	4.9	18
37	<i>Grifola frondosa</i> (Maitake) extract activates PPAR α and improves glucose intolerance in high-fat diet-induced obese mice. 2018 , 82, 1550-1559		11
36	PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. 2019 , 24,		61
35	Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
34	Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	28
33	Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring. 2019 , 8,		19
32	PPAR: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension. 2019 , 2019, 7809216		4
31	Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. 2019 , 144, 377-389		13
30	Nutritional Regulation of Gene Expression: Carbohydrate-, Fat- and Amino Acid-Dependent Modulation of Transcriptional Activity. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	24
29	Reporting temporal fluctuations of hepatic C16 and C18 fatty acids during late gestation and early lactation in dromedary camel. 2019 , 51, 1651-1660		2
28	PPAR α inhibition protects against palmitic acid-LPS induced lipodosis and injury in cultured hepatocyte L02 cell. 2019 , 16, 1593-1603		10
27	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. 2020 , 9,		28
26	Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. 2021 , 50, 101119		8
25	Diet-Induced Physiological Responses in the Liver of Atlantic Salmon (<i>Salmo salar</i>) Inferred Using Multiplex PCR Platforms. 2020 , 22, 511-525		3
24	In utero exposure to phenanthrene induces hepatic steatosis in F1 adult female mice. 2020 , 258, 127360		2
23	Revealing the role of peroxisome proliferator-activated receptor γ in nonalcoholic fatty liver disease. 2021 , 114, 154342		10

22	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. 2021 , 18, 24-39		67
21	Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis. 2021 , 222, 107791		12
20	Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. 2021 , 11, 1519-1539		14
19	Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. 2021 ,		6
18	PPARs in liver physiology. 2021 , 1867, 166097		5
17	The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. 2021 , 13,		8
16	Essential Roles of PPARs in Lipid Metabolism during Mycobacterial Infection. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
15	GDF15 mediates the metabolic effects of PPAR γ by activating AMPK. 2021 , 36, 109501		8
14	PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
13	Signal Transduction and Molecular Regulation in Fatty Liver Disease. 2021 , 35, 689-717		5
12	Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. 2017 , 4,		10
11	Direct control of hepatic glucose production by interleukin-13 in mice. <i>Journal of Clinical Investigation</i> , 2013 , 123, 261-71	15.9	92
10	Distinct but complementary contributions of PPAR isotypes to energy homeostasis. <i>Journal of Clinical Investigation</i> , 2017 , 127, 1202-1214	15.9	174
9	The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective. <i>Current Pharmaceutical Design</i> , 2019 , 25, 2540-2554	3.3	10
8	Binding and activity of bisphenol analogues to human peroxisome proliferator-activated receptor γ . <i>Ecotoxicology and Environmental Safety</i> , 2021 , 226, 112849	7	1
7	The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 6889533	6.7	6
6	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
5	Review: Vascular effects of PPARs in the context of NASH. <i>Alimentary Pharmacology and Therapeutics</i> ,	6.1	0

4	Effects of active, inactive, and derivatives of Akkermansia muciniphila on the expression of the endocannabinoid system and PPARs genes. <i>Scientific Reports</i> , 2022 , 12,	4.9	1
3	The regulation and functions of ACSL3 and ACSL4 in the liver and hepatocellular carcinoma.		0
2	The Role of PPARs in Breast Cancer. 2023 , 12, 130		1
1	Metabolism-Disrupting Chemicals Affecting the Liver: Screening, Testing, and Molecular Pathway Identification. 2023 , 24, 2686		0